Home > Insider Trading > Filing (0001012975-14-000835)

Filing Details

Accession Number:: 0001012975-14-000835
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-12-30 10:09:35
Reporting Period:: 2014-12-26

Filing Date:: 2014-12-30
Accepted Time:: 2014-12-30 10:09:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1337553	Aerie Pharmaceuticals Inc	AERI	Biological Products, (No Disgnostic Substances) (2836)	203109565

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1166285	Michael Steinmetz	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1249153	Dennis Henner	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	Yes	No	Yes	No
1252522	Nicholas Galakatos	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1252523	Robert Liptak	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1252525	Kurt Wheeler	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431403	Nicholas Simon	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431437	Clarus Ventures Ii, Llc	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431439	Clarus Ventures Ii Gp, L.p.	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431443	Clarus Lifesciences Ii, L.p.	C/O Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-12-26	74,510	$30.05	3,529,093	No	4	S	Direct
Common Stock	Disposition	2014-12-29	6,214	$30.03	3,522,879	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was 30.00 to 30.30 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Securities held of record by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLLC and Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.
The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was 30.00 to 30.29 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.